On Thursday, JPMorgan (NYSE:JPM) reiterated its Neutral stance on Patterson Companies (NASDAQ:PDCO), maintaining the $26.00 price target for the company's shares. The firm's assessment followed Patterson's second-quarter fiscal year 2025 results from the dental and animal health distributor, which currently trades at an attractive P/E ratio of 11.7x with a notable 4.75% dividend yield.
The results showcased a revenue beat but were impacted by lower-than-anticipated margins in the Dental segment. According to InvestingPro analysis, Patterson Companies appears undervalued at its current market cap of $1.93 billion. This led to adjusted operating profits falling below expectations, although adjusted earnings per share (EPS) aligned with projections.
Patterson Companies reported an adjusted EPS of $0.47 for the quarter, which was in line with JPMorgan's estimate (JPMe) but slightly below the consensus of $0.49. The company's Dental segment faced margin pressures, but this was somewhat offset by year-over-year margin improvements in the Animal Health division, which also experienced stronger-than-expected top-line growth.
InvestingPro subscribers can access additional insights, including 6 key ProTips and a comprehensive analysis of Patterson's financial health, which currently shows a GOOD overall rating.
The firm noted that Patterson Companies has revised its full-year 2025 adjusted EPS guidance downwards to a range of $2.25 to $2.35, from the previous forecast of $2.33 to $2.43. This new guidance places JPMorgan's and Bloomberg's consensus estimates of $2.33 and $2.32, respectively, towards the upper end of the company's expected earnings range.
Patterson Companies attributed the year-over-year declines to ongoing challenges stemming from the Change Cybersecurity event that affected Dental Value-Added Services (VAS) and a drop in dental equipment sales.
Moreover, the company announced it is considering strategic alternatives, which may include options such as a sale, merger, strategic business combination, or another transaction type. The market is anticipated to closely watch for further details on the strategic review process, including its timeline and extent.
In other recent news, Patterson Companies reported mixed results for the second quarter, with earnings falling short of expectations, while revenue slightly exceeded estimates. The company reported adjusted earnings of $0.47 per share, missing the analyst consensus of $0.49, and revenue rose 1.3% year-over-year to $1.67 billion, slightly above estimates of $1.66 billion.
Patterson's dental segment saw a decline in internal sales of 2.3% compared to the prior year period, while animal health internal sales increased 1.9%.
Additionally, the company revised its fiscal 2025 adjusted earnings guidance to a range of $2.25 to $2.35 per share, differing from the previous analyst consensus of $2.30. Patterson Companies also disclosed it is evaluating potential strategic alternatives to maximize shareholder value, which may include a sale or merger.
In the first half of fiscal 2025, the company returned $96.2 million to shareholders through dividends and share repurchases. These are the recent developments surrounding Patterson Companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.